APC Advanced Proteome Therapeutics Corporation

Caspian Energy Inc. ("Caspian") (TSX VENTURE:CEK.H) advises that each of the
Alberta Securities Commission, the British Columbia Securities Commission and
the Ontario Securities Commission have issued cease trade orders ("Cease Trade
Orders") suspending the trading of the common shares of Caspian. The Cease Trade
Orders result from the Company's delay in filing its audited financial
statements for the year ended December 31, 2013 (the "Annual Financial
Statements"), the related management discussion and analysis ("MD&A") and the
related certification of filings under National Instrument 52-109 -
Certification of Disclosure in Issuers' Annual and Interim Filings. The filings
were due on April 30, 2014 and were not filed as a result of a delay in
receiving audited financial statements from Aral Petroleum Capital LLP ("APC"),
a Kazakhstan partnership in which Caspian indirectly holds a 40% interest. It
was not possible for Caspian to obtain an audit opinion on Caspian's financial
statements without receiving the audited financial statements being prepared for
APC in Kazakhstan, which are incorporated into a footnote in Caspian's financial
statements. All work to be done in Canada relating to Caspian's audited
financial statements was completed prior to the filing deadline. As a result of
the Cease Trade Orders, the NEX board of the TSXV ("NEX") has suspended trading
of Caspian's common shares.


Caspian has now received the audited financial statements from APC and expects
to file the Annual Financial Statements and MD&A this week. Concurrently with
the filing of the Annual Financial Statements and the MD&A, the Company will
apply to the Commissions for revocation of the Cease Trade Orders and upon the
revocation of the Cease Trade Orders, Caspian will submit a reinstatement
application to the NEX. 


This news release contains "forward-looking information" within the meaning of
applicable Canadian securities legislation which we refer to herein,
collectively, as "forward-looking information". Generally, forward-looking
information can be identified by the use of forward-looking terminology such as
"plans", "expects", or "does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or
"believes" or variations of such words and phrases or state that certain
actions, events or results "may", "could", "would", "might", or "will be taken",
"occur", or "be achieved". Caspian's actual performance, developments and/or
results may differ materially from any or all of the forward-looking statements.
Further information which may cause results to differ materially from those
projected in the forward-looking statements is contained in Caspian's filings
with Canadian securities regulatory authorities. All material assumptions used
in making forward-looking information are based on management's knowledge of
current business conditions and expectations of future business conditions and
trends. Although we believe the assumptions used to make such statements are
reasonable at this time and have attempted to identify in our continuous
disclosure documents important factors that could cause actual results to differ
materially from those contained in forward-looking information, there may be
other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such information will prove to be
accurate, as actual results and future events could differ materially from those
anticipated in such information. Accordingly, readers should not place undue
reliance on forward-looking information. We do not undertake to update any
forward-looking information, except in accordance with applicable securities
laws.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Caspian Energy Inc.
Brian Korney
Chief Financial Officer
(403) 513-3375

Advanced Proteome Therap... (TSXV:APC)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024

Advanced Proteome Therap... (TSXV:APC)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024